年轻高危弥漫大B细胞淋巴瘤患者治疗研究进展

Treatment progress of young patients with high-risk diffuse large B-cell lymphoma

弥漫大B细胞淋巴瘤（DLBCL）是成年人淋巴瘤中最常见的一种类型，约占非霍奇金淋巴瘤（NHL）的30％-40％。年轻高危DLBCL患者是临床预后不良的一组特殊人群，目前在临床实践中尚无标准治疗方案，常规化疗、联合利妥昔单抗的R-CHOP、R-CHOP样方案、大剂量化疗及自体造血干细胞移植并未完全扭转其预后不良的现实。文章就年轻高危DLBCL患者的治疗现状及未来的治疗方向进行综述。

Diffuse large B-cell lymphoma （DLBCL） is the most common adult lymphoid malignancy accounting for 30 %-40 % of all non-Hodgkin lymphoma （NHL）. Young patients with high-risk DLBCL as a special group with poor clinical prognosis still can not receive standard treatment protocols in clinical practice at present. Conventional chemotherapy, combination of rituximab （R） to conventional CHOP chemotherapy, R-CHOP-like protocol, high-dose chemotherapy and autologous hematopoietic stem cell transplantation have not fully reversed the poor prognosis. This review focuses on the recent advances and future direction in the treatment of the young patients with high-risk DLBCL.